Literature DB >> 7053814

Myosarcomas of the stomach: natural history, prognostic factors and management.

M H Shiu, G H Farr, D N Papachristou, S I Hajdu.   

Abstract

A retrospective study was made of 41 patients treated for gastric myosarcoma to identify prognostic factors that influence results. The adjusted five- and ten-year survival rates were 56% and 43% respectively, with no significant difference between leiomyosarcoma and malignant leiomyoblastoma. A histopathologic grade of malignancy could be assigned to each tumor according to the degree of hypercellularity, nuclear abnormality, mitotic rate and other characteristics. High histopathologic grade, large tumor size (greater than 5 cm diameter) and invasion of adjacent organs adversely affected prognosis. Five-year survival after curative treatment was: 100% (9/9) for small tumors, of which six were treated by wedge gastric resection; 67% (8/12) for large tumors, mostly after subtotal gastrectomy; and 0% for tumors that invaded adjacent organs, despite extended resections. It is concluded that the management of gastric myosarcomas can be planned according to these prognostic factors and that multimodal therapy of tumors with adverse factors warrants consideration.

Entities:  

Mesh:

Year:  1982        PMID: 7053814     DOI: 10.1002/1097-0142(19820101)49:1<177::aid-cncr2820490136>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  59 in total

1.  [Leiomyosarcoma of the esophagus. Clinical aspects, diagnosis and therapy based on an individual case].

Authors:  A C Pesarini; H Ernst; C Ell; C Wittekind; E G Hahn
Journal:  Med Klin (Munich)       Date:  1997-04-15

2.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

3.  Sporadic somatic mutation of c-kit gene in a family with gastrointestinal stromal tumors without cutaneous hyperpigmentation.

Authors:  Chun-Nan Yeh; Tsung-Wen Chen; Yi-Yin Jan
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

4.  Pedunculated gastrointestinal stromal tumor presenting as bowel volvulus: usefulness of color Doppler ultrasonography for strangulated ileus.

Authors:  Takehiro Nakai; Tomoo Shimomura; Hiroaki Nakai; Yoshio Suzuki; Masami Nakamura; Tadashi Kawasaki
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 5.  Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach.

Authors:  Robert J Coffey; Mary Kay Washington; Christopher L Corless; Michael C Heinrich
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

6.  Surgical margin status and prognosis of gastrointestinal stromal tumor.

Authors:  António M Gouveia; Amadeu P Pimenta; Ana F Capelinha; Dionísio de la Cruz; Paula Silva; José M Lopes
Journal:  World J Surg       Date:  2008-11       Impact factor: 3.352

7.  Endoscopic submucosal dissection for treatment of gastric submucosal tumors originating from the muscularis propria layer.

Authors:  Shuo Zhang; Guan-Qun Chao; Men Li; Gui-Bao Ni; Bin Lv
Journal:  Dig Dis Sci       Date:  2013-02-05       Impact factor: 3.199

8.  Expression of Ets-1 proto-oncoprotein in gastrointestinal stromal tumors, leiomyomas and schwannomas.

Authors:  Toshiyuki Nakayama; Ayumi Yoshizaki; Shinji Naito; Chun-Yang Wen; Gabit Alipov; Yuichi Yakata; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

9.  Gastrointestinal stromal tumours: outcomes of surgical management and analysis of prognostic variables.

Authors:  Haluk R Unalp; Hayrullah Derici; Erdinc Kamer; Ali D Bozdag; Ercument Tarcan; Mehmet A Onal
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

10.  Neurofibroma of the stomach: report of a case.

Authors:  Y Murao; S Miyamoto; H Nakano; S Imai; T Ozawa; A Hirai; R Nunotani
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.